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1. Introduction 
Tacrolimus (FK506, Prograf®), a calcineurin inhibitor, is widely prescribed as an 
immunosuppressive drug for solid organ transplant recipients. Dose adjustment based 
on therapeutic drug monitoring (TDM) leads to better clinical outcome, especially in 
pediatric transplant recipients (1, 2)]. Most clinical laboratories use either immunoassay 
or liquid chromatography-tandem mass spectrometry (LC-MS/MS) to measure 
tacrolimus. 
Automated immunoassays provide quick turnaround time but lack 
standardization across platforms, and may suffer from cross reactivity with tacrolimus 
metabolites (3). When clearance is impaired, leading to buildup of drug metabolites, 
such cross-reactivity can result in a significant over-estimation of the tacrolimus 
concentration. Additionally, the cost-per-test for immunoassay is higher than for mass 
spectrometry (MS) assays (4, 5). Many of the tacrolimus immunoassays still require 
manual sample pretreatment before automated analysis by the instrument, while only a 
selective few may include on-board hemolysis of whole blood specimens to be truly 
automated. 
LC-MS/MS methods have superior analytical specificity and lower reagent cost, 
especially if one considers the ability to multiplex several different immunosuppressive 
drugs. However, they usually require more specimen pretreatment, such as protein 
precipitation and/or extraction, and are therefore almost always performed in batch 
mode to improve efficiency.  This results in longer turnaround times, which may delay 
adjustment of dose especially during the early phase of prophylaxis of allograft 
rejection. In addition, maintaining LC-MS/MS test methods in clinical laboratories 
require considerable amount of expertise and resource, which are more often spent on 
liquid chromatography system up keeping and troubleshooting to minimize system 
downtime. 
Paper spray (PS) is a direct technique that generates gas phase analyte ions 
directly from dried blood spots (DBS) or other fluids without the need for complex 
sample pretreatment and chromatography (6, 7). Sample extraction and ionization are 
all performed in automated fashion by the PS ion source directly from a paper substrate 
stored within a single-use cartridge (Figure 1).  There is no punching, no offline 
extraction, and total analysis time (excluding time required to dry the sample) is only a 
few minutes. Compared to conventional LC-MS/MS methods, this new approach has 
the additional advantages of significant reduction of solvent/reagent waste and 
elimination of carry-over. 
Briefly, paper spray-tandem mass spectrometry (PS-MS/MS) is performed by 
depositing whole blood and internal standard mixture onto a paper substrate and 
allowing it to dry. An appropriate solvent is applied to the rear of the paper so that it 
flows through the dried blood spot sample by capillary action. As the solvent wicks 
through the sample, soluble components are extracted into the solvent, leaving behind 
the bulk of proteins and lipids [6].  A high voltage (3-5 kV) is applied to the moist paper, 
and an electrospray is induced at the sharp tip of the triangular shaped paper in the 
cartridge, which is held stationary in front of the inlet to the MS. As solvent evaporates, 
gas phase ions of the analyte molecules are generated which can then be detected by 
MS. PS-MS/MS has been successfully used for quantitative analysis of xenobiotics (8-
10) and endogenous compounds (11) from whole blood.  
We evaluated the feasibility of this novel approach for tacrolimus TDM in our 
clinical diagnostic laboratory. Tacrolimus was the drug of choice for the study due to the 
high clinical demand for TDM as well as the highly desirable fast turnaround time. This 
is the first application of this technology in a clinical diagnostic laboratory, and the first 
reported cross-validation of a paper spray assay against validated FDA approved 
immunoassays and LC-MS/MS assays. 
 
2. Materials and Methods 
2.1. Preparation of reagents, standards, and QCs 
 FK506 monohydrate (MW 822; ≥98% purity) was purchased from Sigma-Aldrich 
(St. Louis, MO). Tacrolimus (MW 804, certified 1 mg/ml in acetonitrile; 99.4% purity) 
was purchased from Cerilliant (Round Rock, TX). Stable isotope labeled internal 
standard (SIL-IS) of [13C, 2H2]-FK506 (MW 807; 98% isotopic purity) was purchased 
from Toronto Research Chemicals (Toronto, Canada). Liquichek whole blood 
immunosuppressant levels 1, 2, 3 and 4 (Bio-Rad, Hercules, CA) and Tac Control levels 
1, 2 and 3 (More Diagnostics; Los Osos, CA) were used as quality controls (QCs). 
HPLC grade methanol was purchased from VWR (Radnor, PA). Chloroform was 
purchased from EMD Millipore (Billerica, MA). Sodium acetate anhydrous (NaOAc) was 
purchased from Sigma-Aldrich. All other drugs and chemicals used were of highest 
purity commercially available. FK506 monohydrate powder was carefully weighed and 
dissolved in methanol to obtain a 1 mg/ml stock solution.  The stock was further diluted 
in methanol to obtain working stock solutions. Calibration standard solutions of 
tacrolimus at various concentrations were obtained by spiking pure FK506 solutions into 
FK506-free whole blood, keeping the organic solvent content at less than 5%. A 
separate tacrolimus stock solution from Cerilliant was used to confirm concentrations of 
tacrolimus stocks made in-house. Tacrolimus and its SIL-IS solutions were checked for 
impurity. 
 
2.2. Sample pretreatment 
 A 200 μl aliquot of patient whole blood collected in K2EDTA collection tube, 
calibration standards (at 0, 0.5, 3.0, 10.0, and 30.0 ng/ml) prepared in drug free pooled 
whole blood, or QC material was transferred to labeled sample vials and mixed well with 
50 μl of SIL-IS solution ([13C, 2H2]-FK506 at 30 ng/ml). An aliquot (10 μl) of each of the 
sample mixtures was then carefully spotted onto the middle of dry porous triangular 
shaped paper (Whatman 31ET-Chr) contained in disposable cartridges (Prosolia, 
Indianapolis, IN) following manufacturer’s instructions. Drying of the blood spots was 
accelerated by loading up to 40 cartridges into the cartridge holder and placing it in an 
oven at 40°C for 20 min, or by placing up to 8 cartridges in a cartridge dryer provided by 
Prosolia which blows warm (~37°C) air over the blood spots for 20 min. Cartridges could 
otherwise be left at ambient temperature for about 90 minutes until they are completely 
dry. Result comparison was performed between replicate blood spotted cartridges being 
dried under different conditions and at different length of time, such as room 
temperature, drying by the cartridge dryer, and drying in oven at 40°C. Comparison 
study was performed by using different blood volume of 200 μl, 100 μl and 50 μl, with 
proportionally reduced SIL-IS solution volume of 50 μl, 25 μl, and 12.5 μl, respectively. 
 
2.3. Ion source and MS/MS optimization 
 Sample analysis was performed using an automated paper spray ion source 
(Prosolia) interfaced to a TSQ Vantage triple quadrupole mass spectrometer (Thermo 
Scientific, San Jose, CA). The paper spray ion source serves the combined functions of 
an auto-sampler and ionization source, in automatically loading the cartridges in the 
instrument, delivering the solvent, positioning the cartridge in front of the MS inlet, and 
ejecting the spent cartridge after analysis. The paper spray ion source is latched on to 
the front of the MS using a mechanism similar to the commercial ion source housing but 
is specifically designed and made for the make and model of the MS. The ion source 
was programed to deliver the extraction/spray solvent (40% Methanol and 60% 
Chloroform, 0.1% NaOAc; 170 μl) to the cartridges at an optimal rate to extract and 
elute analytes to the tip of the paper by capillary action. Sodium acetate was included to 
1) increase the stability of the spray ionization by increasing solvent conductivity and 2) 
facilitate the generation of sodium adducts of tacrolimus and its SIL-IS. After the solvent 
application, the automated ion source moved the cartridge in line with the MS inlet, with 
the sharp tip of the paper positioned about 4 mm away from the inlet. An ionization 
voltage of +3.4 kV was applied, initiating production of analyte ions from the tip of the 
paper which were drawn directly into the MS inlet. More information about experimental 
and fundamental details can be found in the literature (8, 9, 12). MS conditions were 
optimized using continuous infusion of tacrolimus and SIL-IS solutions into the 
commercial H-ESI source by a syringe pump, and SRMs for both compounds selected 
accordingly (Table 1). XCalibur software (Thermo Scientific) was used to control the MS 
and to process data.  
For the SIL-IS, [13C,2H2]-FK506 was listed as the major component, but due to 
impurities in the compound, the +4 m/z peak at m/z 830 was nearly as intense.  This 
peak at m/z 830 was used during analysis to reduce overlap between the SIL-IS and the 
naturally occurring isotope peaks of the unlabeled tacrolimus. 
 
2.4. Data collection and analysis 
 Data was collected for 60 seconds by toggling the spray voltage on and off, 
resulting in a total of 50 scans for each SRM channel. The average time required per 
sample analysis was 3 minutes, which included extraction and data collection. The more 
intense of the two SRMs (m/z 826 → 616 for tacrolimus and m/z 830 → 620 for the IS) 
was used for quantitation, while the other transition was used for confirmation. The area 
under the curve (AUC) for the tacrolimus quantifier ion during the entire 60 second 
analysis was determined and normalized by that of the SIL-IS quantifier ion. No 
background subtraction was performed. A calibration curve was constructed by linear 
regression (without weighting) from calibration standards analyzed within the same 
batch, and used for calculation of all patient sample concentrations as well as QCs for 
that batch. Tacrolimus results were confirmed when the quantifier and qualifier SRM 
ions were averaged over the entire scan time and ratio of the two was within mean 
±25%. 
 
2.5. Method validation 
 PS-MS/MS assay was evaluated for intra-day (n=10) and inter-day (n=12) 
imprecision using QC materials at multiple levels of tacrolimus (Bio-Rad and More 
Diagnostics). Imprecision was further evaluated by repeatedly analyzing patient 
samples (n=95) with known tacrolimus concentration (0.0-29.0 ng/ml) everyday over 3-5 
days in order to generate a precision profile. Assay linearity was evaluated by serial 
dilution of the highest calibration standard in drug free whole blood (8 levels). Limit of 
detection (LOD) was defined as three times the standard deviation of the reading 
obtained from drug free blood divided by the slope of the calibration curve (3* sb/m) 
(13). The lower limit of quantitation (LLOQ) was determined by 1) determining interday 
test imprecision in patient samples with varying tacrolimus concentrations and 2) 
calculating the LLOQ using a statistical approach (10*sb/m)(13). The LLOQ was set at a 
concentration where the imprecision decreased to less than 20% and was also greater 
than 10*sb/m. Assay accuracy was determined by the closeness of quantitative results 
to their predetermined concentrations measured in samples spiked with pure tacrolimus. 
Accuracy was further evaluated by comparing PS-MS/MS results to those obtained by 
validated FDA approved immunoassays (Architect, Abbott Diagnostics, Abbott Park, IL; 
Dimension RXL, Siemens, Malvern, PA), an LC-MS/MS assay validated in-house, and a 
validated LC-MS/MS method performed at a reference laboratory (Mayo Clinic 
Laboratories, Rochester, MN). Robustness of the method was evaluated by testing the 
effects of hemolysis, lipemia and icterus.  Specificity was evaluated by spiking patient 
samples of known tacrolimus concentration at low and medium therapeutic ranges, with 
high concentrations of each of 25 pure steroid, vitamin, diuretic, and 
immunosuppressive compounds (f/c: 200-500 ng/ml). Selected sample cartridges were 
dried and analyzed a second time to determine the feasibility of repeat analysis without 
re-spotting sample. Study was also carried out to compare results from different batches 
using a common single calibration, versus results from multiple batches using 
calibration included in each batch. 
 
Note on terminology 
 The term chronogram is used here to indicate ion signal as a function of time.  
Use of the more commonly used term “chromatogram” is discouraged because no 
chromatography (i.e. separation of analytes) is being performed.   
 
3. Results 
 
3.1. Optimization 
 An extraction/spray solvent composition of 40% methanol, 60% chloroform 
containing 0.1% NaOAc was found to be optimal to generate tacrolimus signal with 
maximum intensity and duration. Reconstituted tacrolimus and its SIL-IS solutions were 
checked for impurity, and no contaminant compound or unlabeled tacrolimus was found 
in SIL-IS solutions. Continuous syringe pump infusion experiments revealed abundant 
sodium adducts of tacrolimus (m/z 826.5) in full mass scan. Ammonium adducts (NH4+) 
could also be generated at similar intensities by spiking ammonium acetate into the 
solvent rather than sodium acetate.  The sodium adduct of tacrolimus was deemed to 
give more selective fragment ions during MS/MS, and was therefore chosen over the 
ammonium adduct for this assay. The two most intense product ions and the optimal ion 
source and MS instrument settings were obtained and used for SRM analysis (Table 1). 
Cartridges spotted with pure tacrolimus and SIL-IS solutions were dried and used to 
confirm the settings and SRM selections.  Different drying conditions tested had no 
impact to tacrolimus results. Sample mixture preparation using smaller blood aliquots of 
100 μl and 50 μl gave equivalent test results, and 200 μl was selected for the method. In 
case of insufficient blood samples submitted, especially by pediatric and anemic 
transplant patient, a lower sample volume may be used. 
 
3.2. Interference study 
 During paper spray analysis, the chemicals extracted from the DBS are 
introduced directly to the mass spectrometer without prior separation or extraction.  
Because of this lack of pretreatment, the effect of hemolysis, lipemia, and icterus on 
analyte ion intensity was evaluated in comparison to that of pure compound solutions (in 
methanol) and of regular whole blood samples without visible hemolysis, lipemia, or 
icterus. There was no systematic difference in the AUC or the shape of the chronogram 
between these groups. Variability in the shape of the chronograms was observed, but it 
was not consistently associated with particular samples. The similarity of the SIL-IS 
chronogram from the same sample essentially normalized such variability (Figure 2), 
providing reliable quantitative results. Experience from analysis of hundreds of patient 
samples revealed that up to 10% samples required reanalysis due to failure of the initial 
sample cartridge to generate adequate signal intensity and/or failure of the preset ion 
ratio criterion. Up to 90% of repeat analysis was successful, however, and was able to 
meet the ion ratio criteria and produce quantitative results.  On rare occasions, a 
sample may need to be repeated a third time, usually after making dilution, to generate 
successful ionization and quantitative result. 
 3.3. Precision, linearity, and accuracy 
 The inter-day precision (n=10) for the analysis of Bio-Rad QC materials was 
12%, 14%, 14%, and 12% CV at tacrolimus concentrations of 4, 9, 16, and 25 ng/ml, 
respectively. Analysis of a different set of QC materials (More Diagnostics) showed 
inter-day precision (n=12) to be 13%, 8%, and 5%, at tacrolimus concentration of 4.5, 
10.5, and 24.5 ng/ml, respectively. Bio-Rad control samples appeared to result in higher 
imprecision than the other QC samples, possibly due to difference in sample matrix, 
where the two manufacturers may include a number of different proprietary additives. 
The assay was linear within the analytical measurement range of 1.5-30 ng/ml as 
determined by serial dilution of the highest calibration standard with drug free whole 
blood, as was also demonstrated by the typical calibration curve (Figure 3). The assay 
accuracy was evaluated by quantifying standards prepared in drug free whole blood 
spiked with certified of tacrolimus standard solution. The accuracy of the assay was 
within 95-105%. Accuracy was also evaluated by comparing the concentrations 
determined by PS-MS/MS to those determined by two immunoassays and two LC-
MS/MS assays. Linear regression analysis (y = mx +b) was used for the assessment 
with the following slope (m) and y-intercept (with 95% confidence limit): (1) to Siemens 
Dimension RXL (Figure 4A): m = 0.87-1.01, b = -0.61-0.79; difference of mean = 0.4 
ng/ml. (2) to Abbott Diagnostics Architect (Figure 4B): m = 0.98 -1.06, b = -0.22-0.71; 
difference of mean = 0.3 ng/ml. (3) to LC-MS/MS at a reference lab (Figure 4C): m = 
0.83-0.96, b = -0.20-1.04; difference of mean = 0.5 ng/ml. (4) to LC-MS/MS method 
developed in-house (Figure 4D): m = 0.89-1.0, b = -0.82-0.28; difference of mean = 0.7 
ng/ml. Finally, recent external proficiency samples from CAP (College of American 
Pathologists) were analyzed and results were at the LC-MS/MS peer group mean (data 
not shown). 
 
3.4. Limits of detection and quantitation. 
 The limit of detection was determined by repeat analysis of whole blood samples 
without tacrolimus to obtain the mean and standard deviation for the blank signal (N = 
25 over 17 different days). The LOD, calculated using 3*sb/m, was 0.2 ng/mL. The 
LLOQ was determined by plotting precision as a function of concentration in patient 
samples (Figure 5) and determining the concentration at which the %CV was less than 
20%. Additionally, the LLOQ was calculated from the formula 10*sb/m, which gave a 
concentration of 0.7 ng/mL. The LLOQ was conservatively set at 1.5 ng/mL using these 
two criteria. This LLOQ was further confirmed by determining test imprecision at various 
tacrolimus concentration of spiked drug free whole blood sample. 
 
3.5. Ion suppression and recovery 
 Matrix effects were evaluated by comparing the absolute signal of the SIL-IS 
(calculated as the area under the curve for the quantifier ion) in methanol versus pooled 
whole blood. Calibration standards in methanol and drug free whole blood were 
prepared and analyzed on three separate days.  The absolute signal of the SIL-IS for 
the calibrators prepared in methanol, averaged across all three days, was 1.3E5 
compared to 3.6E4 when prepared in whole blood.  This is a relative difference of 3.5 
fold, with a 95% confidence interval of 2.7 to 4.5.  The higher SIL-IS signal in methanol 
compared to whole blood likely arises from a combination of lower analyte recovery 
from the dried blood matrix and ion suppression.   
 Difference in matrix effect among patient samples was also evaluated.  Thirty 
three random patient blood samples were analyzed on three consecutive days. The 
average absolute signal of the SIL-IS obtained for each patient sample was compared 
to the average signal obtained for all of the samples.  None of the patient samples were 
significantly different from the pooled mean at the 95% confidence level, indicating that 
no significant differential ion suppression/recovery effects existed in this group.    
 
3.6. Specificity and reanalysis of cartridges 
 No detectable difference was noted in samples with low and medium tacrolimus 
concentrations after spiking high concentrations of each of 25 pure steroid, vitamin, 
diuretic, and immunosuppressive drugs up to final concentrations of 500 ng/ml.  Due to 
the need to reanalyze samples, we examined the option of reanalyzing cartridges 
containing patient blood spots. The reanalysis was carried out after drying the cartridges 
(n=40) a second time following the first analysis. Thirty repeat analyses using the same 
cartridge produced comparable results, while 10 (25%) repeat analyses had spurious 
results, leading to the conclusion that using a new cartridge for repeat analysis was 
necessary. 
 
Discussion and Conclusion 
 We evaluated PS-MS/MS for TDM of tacrolimus in a clinical diagnostic 
laboratory. The method was tested with real patient samples, and was shown to be 
simple and rapid. The method uses simple sample pretreatment and completely 
eliminated chromatography, which simplified the analysis of tacrolimus by MS while 
retaining the superb sensitivity and specificity. To maintain high precision and accuracy, 
the method used a SIL-IS to better control the variability arising during the analysis, 
particularly during extraction of the drug from the DBS and also during ion generation 
from the paper tip.  
 The instrumental analysis time for PS-MS/MS was comparable to many typical 
tacrolimus LC-MS/MS assays. PS-MS/MS had some other advantages over more 
traditional HPLC-MS/MS methods for tacrolimus quantitation, however. First, the 
sample preparation steps are simpler because blood cell lysis, protein precipitation, and 
centrifugation steps can be omitted. The simplification of the sample preparation 
improved turnaround times and made the method more amenable to random access 
analysis. Second, because PS-MS/MS required less bench work and simplified the 
analytical measurement process and instrumentation by removing the HPLC system, 
there is a potential for reductions in labor and expertise requirements to maintain and 
perform an MS based assays. Third, solvent consumption was lower, and practically no 
solvent waste (<1 mL per day) was generated. Fourth, aside from the solvent no 
components of the system require regular replacement, unlike the analytical column in 
an HPLC based assay.  Finally, there is no potential for carry-over because the 
ionization, extraction, and fluid path are contained within a disposable cartridge. 
 Because extraction and ionization occur simultaneously in PS and cannot be 
separated, we evaluated matrix effects as a whole (including both ion suppression and 
recovery) by comparing the absolute signal of the SIL-IS in calibrators prepared in 
methanol and drug free whole blood.  Signal for calibrators prepared in methanol was 
about 3.5 times higher than in whole blood calibrators.  This difference likely arises from 
a combination of ion suppression and poorer recovery from the dried blood matrix 
compared to paper alone.  It should be noted that the presence of matrix effects does 
not prevent accurate quantitation.  Indeed, many clinical assays are well-known to 
exhibit matrix effects.  In the PS-MS/MS assay developed here, matrix matched whole 
blood calibrators and a stable isotope labeled internal standard were used to account 
for variation arising during extraction and ionization, and resulted in a much simplified 
MS method with satisfactory accuracy and precision.  Moreover, comparison of 33 
different patient samples showed no significant difference in internal standard response 
among the patient samples.  
 Tacrolimus is normally detected by MS as the ammonium adduct.  For the PS-
MS/MS assay developed here, we chose to detect tacrolimus as sodium adduct instead 
for several reasons. First, the three most abundant fragment ions obtained for the 
[M+Na]+ ion were about 2 to 3 times more intense than the [M+NH4]+ ion.  Second, the 
fragmentation for the [M+Na]+ ion was deemed to be more selective because the most 
intense fragment ions, which were m/z 616, 415, and 445, arose from relatively large 
neutral losses, whereas the two most intense fragment ions for the [M+NH4]+ ion arose 
from neutral losses of only 34 and 53 amu.  Larger neutral losses, particularly those that 
result in fragment ions in the middle of the mass range, tend to be more selective. This 
consideration becomes even more important in PS-MS/MS due to the elimination of 
chromatography. Finally, a number of tacrolimus LC-MS/MS assays using tacrolimus 
sodium adduct were in published reports (14, 15).  
The whole blood volume required per sample analysis was as little as 50 µl.  The 
total sample volume required for the assay was set by the need to mix an accurate 
volume of the blood with the IS solution.  In this report, 200 µl of blood sample was 
used, but this could be reduced to 50 µl or less, provided the blood volume was 
measured accurately. Reduction of the blood draw volume would be ideal for pediatric 
organ transplant patients, in which poor circulation and anemia are common. Another 
feature of PS-MS/MS is that the assay is performed on DBS. Because of the relative 
ease of storage and transportation of DBS (16), the method may be amenable to off-site 
blood collection in clinics with a simple finger prick collection. Further development to 
the blood collection cartridge and method validation would be required prior to taking 
this step. 
The novel approach of PS-MS/MS is suitable for therapeutic monitoring of 
tacrolimus.  The PS-MS/MS method reported here for tacrolimus had excellent LLOQ 
and accuracy, and was found to be well suited for a clinical lab with limited expertise in 
the maintenance and trouble shooting of LC-MS/MS.  PS-MS/MS cannot replace LC-
MS/MS for all applications, particularly where closely related isomers must be 
distinguished (e.g. testosterone and DHEA or morphine and norcodeine). This study 
demonstrates that PS-MS/MS is a viable alternative method for tacrolimus 
measurement, having lower ongoing costs than immunoassays and being more easily 
implemented in some clinical labs than LC-MS/MS because it eliminates 
chromatography and associated user training and trouble shooting, generates very little 
solvent waste (around 1 ml/day), and requires much less sample preparation.   
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 Table 1. TSQ Vantage MS/MS and SRM Parameters 
Name Paren
 
Produc
 
Width Time (s) CE Q1 PW Q3 PW S-Lens 
FK506 
[M + Na]+ 
 
 
826.5 443.1 0.01 0.1 44 0.30 0.70 182 
826.5 616.3 0.01 0.1 32 0.30 0.70 182 
FK506-13C,2H2 
[M + Na]+ 
 
830.5 447.2 0.01 0.1 44 0.30 0.70 182 
830.5 620.3 0.01 0.1 32 0.30 0.70 182 
Parent: parent ion; Product: product ion; CE: collision energy; PW: peak width 
Figure Captions 
Figure 1. Schematic demonstrating the workflow for a PaperSpray analysis. 
Figure 2. Rows 1-3: Representative PS-MS/MS data for three patient samples; Left 
column shows the extracted ion chronograms for the sodium adducts of tacrolimus (m/z 
826 → 616, solid line) and the SIL tacrolimus (830 → 620, dashed line). Right column 
shows the stick SRM spectra for the quantifier ion (m/z 826 → 616) and qualifier ion 
(m/z 826→ 443) to show the ion ratio for the three patient samples   
 
Figure 3. PS-MS/MS calibration curve. 
 
Figure 4. Method comparison with two immunoassays (A and B) assays and two HPLC-
MS/MS assays. 
 
Figure 5. PS-MS/MS precision profile for 95 patient showing interday precision as a 
function of concentration 
Charged droplets  
3.5 kV 
Inlet to mass spectrometer 
Extraction/spray 
solvent (170 µL) 
1) Add internal   
standard 
2) Spot blood 
onto paper 
3) Analyze by paper spray MS 
Internal 
standard 
solution 
Blood sample 
Figure 1 
0.0 0.2 0.4 0.6 0.8 1.0 1.2 
Time (min) 
20 
40 
60 
80 
100 
20 
40 
60 
80 
100 
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
 
0 
m/z 826 → 616 
[tacrolimus+Na]+ 
 
m/z 830 → 620 
[SIL tacro+Na]+ 
m/z 
0 
20 
60 
80 
100 
40 
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
 
443.1 
616.3 
0.0 0.2 0.4 0.6 0.8 1.0 1.2 
Time (min) 
20 
40 
60 
80 
100 
20 
40 
60 
80 
100 
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
 
0 
m/z 826 → 616 
[tacrolimus+Na]+ 
 
m/z 830 → 620 
[SIL tacro+Na]+ 
 
m/z 
0 
20 
60 
80 
100 
40 
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
 
443.1 
616.3 
0.0 0.2 0.4 0.6 0.8 1.0 1.2 
Time (min) 
20 
40 
60 
80 
100 
20 
40 
60 
80 
100 
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
 
0 
m/z 826 → 616 
[tacrolimus+Na]+ 
 
m/z 830 → 620 
[SIL tacro+Na]+ 
 
m/z 
0 
20 
60 
80 
100 
40 
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
 
443.1 
616.3 
(1) 
(2) 
(3) 
Figure 2 
02
4
6
8
10
12
0 5 10 15 20 25 30
A
U
C
 o
f 
ta
cr
o
lim
u
s 
/ 
A
U
C
 o
f 
IS
 
Tacrolimus concentration in blood (ng/mL) 
Calibrators
least squares fit
Figure 3 
y = 1.0x - 0.02 
R² = 0.99 (n=40) 
0
5
10
15
20
25
30
35
40
0 5 10 15 20 25 30 35
Architect (ng/mL) 
P
S-
M
S/
M
S 
(n
g/
m
L)
 
y = 0.95x + 0.4  
R² = 0.90 (n=75) 
0
5
10
15
20
25
0 5 10 15 20 25
Dimension RXL (ng/mL) 
P
S-
M
S/
M
S 
(n
g/
m
L)
 
y = 0.95x - 0.2 
R² = 0.97 (n=52) 
0
5
10
15
20
25
30
35
40
0 5 10 15 20 25 30 35 40
LC-MS/MS (ng/mL; API5500) 
P
S-
M
S/
M
S 
(n
g/
m
L)
 
y = 0.9x + 0.4 
R² = 0.93 (n=60) 
0
5
10
15
20
25
0 5 10 15 20 25
LC-MSMS (ng/mL; Reference Lab) 
P
S
-M
S
/M
S
 (
n
g
/m
L
) 
A) B) 
D) C) 
Figure 4 
n = 95 
0
20
40
60
80
100
0 5 10 15 20 25
FK506 concentration (ng/mL) 
C
V
 (
%
) 
